GRP and neoplasm: Elevated ProGRP levels are associated with poor outcomes of neoadjuvant chemoimmunotherapy and tumor recurrence and may help predict prognosis and screen patients more suitable for PD-(L)1 blockade immunotherapy-based neoadjuvant treatment in LS-SCLC.